59772-31-5

Usage

Uses

N-(2,6-Difluorophenyl)thiourea is used in the preparation of anti-tubercular agents

InChI:InChI=1/C7H6F2N2S/c8-4-2-1-3-5(9)6(4)11-7(10)12/h1-3H,(H3,10,11,12)

Upstream product

• 5509-65-9 2,6-difluoroaniline 

Downstream Products

• 1187669-30-2 N-(2,6-difluorophenyl)-4-(4-pyridinyl)-1,3-thiazol-2-amine 
• 1269487-65-1 (4S)-4-(N-benzyloxycarbonyl-2-aminoethyl)-2-[(2,6-difluorophenyl)amino]imidazoline hydrochloride 
• 1269603-75-9 (4S)-4-(N-benzyloxycarbonyl-2-aminoethyl)-2-[(2,6-difluorophenyl)amino]imidazoline 
• 59772-32-6 C₈H₈F₂N₂S*HI 

Relevant academic research and scientific papers

High-throughput screen for inhibitors of protein-protein interactions in a reconstituted heat shock protein 70 (Hsp70) complex

Protein-protein interactions (PPIs) are an important category of putative drug targets. Improvements in high-throughput screening (HTS) have significantly accelerated the discovery of inhibitors for some categories of PPIs. However, methods suitable for s

Synergism of fused bicyclic 2-aminothiazolyl compounds with polymyxin B against: Klebsiella pneumoniae

A series of fused bicyclic 2-aminothiazolyl compounds were synthesized and evaluated for their synergistic effects with polymyxin B (PB) against Klebsiella pneumoniae (SIPI-KPN-1712). Some of the synthesized compounds exhibited synergistic activity. When 4 μg ml-1 compound B1 was combined with PB, it showed potent antibacterial activity, achieving 64-fold reduction of the MIC of PB. Furthermore, compound B1 showed prominent synergistic efficacy in both concentration gradient and time-kill curves in vitro. In addition, B1 combined with PB also exhibited synergistic and partial synergistic effect against E. coli (ATCC25922 and its clinical isolates), Acinetobacter baumannii (ATCC19606 and its clinical isolates), and Pseudomonas aeruginosa (Pae-1399).

THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS

Invented is a method of inhibiting the activity/function of PI3 kinases using substituted thiazolones. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of substituted thiazolones.